Trials / Completed
CompletedNCT00237939
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,200 (planned)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2005-10-13
- Last updated
- 2013-11-08
Locations
20 sites across 5 countries: Belgium, France, Netherlands, Portugal, Spain
Source: ClinicalTrials.gov record NCT00237939. Inclusion in this directory is not an endorsement.